Related Experiment Video
Updated: Aug 7, 2026
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
Published on: January 20, 2019
Epigenetic silencing of multiple genes in primary CNS lymphoma
Linda C Chu1, Charles G Eberhart, Stuart A Grossman
1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
Abstract:
Epigenetic silencing of functionally important genes is important in the development of malignancies and is a source of potential markers for molecular detection. Primary central nervous system lymphoma (PCNSL) is an increasingly common tumor that has not been extensively examined for changes in promoter region methylation. We examined 14 tumor suppressor genes in 25 cases of PCNSL using methylation-specific PCR. Methylation was observed in DAPK (84%), TSP1 (68%), CRBP1 (67%), p16(INK) (4a) (64%), p14(ARF) (59%), MGMT (52%), RARbeta2 (50%), TIMP3 (44%), TIMP2 (42%), p15(INK) (4b) (40%), p73 (28%), hMLH1 (12%), RB1 (8%) and GSTP1 (8%). Promoter methylation of p14(ARF), p16(INK) (4a) and MGMT was correlated with loss of expression by immunohistochemical staining. The methylation of many of these genes in PCNSL is similar to that reported in other high-grade B-cell lymphomas. All 25 cases of PCNSL had methylation of at least 2 genes. Methylation of DAPK, p16(INK) (4a) or MGMT was found in 96% of the tumors, suggesting simple marker strategies to detect circulating methylated DNA in serum that might facilitate early tumor detection. Our study provides insight into the epigenetic alterations in PCNSL and provides potential biomarkers of disease.
Insights
Epigenetic silencing of genes is crucial in cancer development. This study found widespread gene promoter methylation in primary central nervous system lymphoma (PCNSL), identifying potential biomarkers for early tumor detection.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Epigenetic gene silencing is a key mechanism in malignancy development.
- Primary central nervous system lymphoma (PCNSL) is an aggressive tumor with limited research on promoter methylation.
- Identifying epigenetic alterations can reveal potential molecular detection markers.
Purpose of the Study:
- To investigate promoter region methylation of 14 tumor suppressor genes in PCNSL.
- To correlate methylation status with gene expression.
- To identify potential biomarkers for PCNSL detection.
Main Methods:
- Methylation-specific PCR was used to analyze promoter methylation in 25 PCNSL cases.
- Immunohistochemical staining assessed gene expression.
- Data analysis correlated methylation patterns with clinical data.
Main Results:
- Widespread methylation was observed across 14 tumor suppressor genes, with DAPK (84%) and TSP1 (68%) showing the highest rates.
- Promoter methylation of p14(ARF), p16(INK)(4a), and MGMT correlated with reduced protein expression.
- All PCNSL cases exhibited methylation of at least two genes, and 96% showed methylation in DAPK, p16(INK)(4a), or MGMT.
Conclusions:
- Epigenetic alterations, specifically gene promoter methylation, are prevalent in PCNSL.
- The frequent methylation of specific genes (DAPK, p16(INK)(4a), MGMT) suggests their utility as biomarkers for PCNSL.
- Detecting methylated DNA in serum could facilitate early diagnosis of PCNSL.
More Related Videos
11:50Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN
Published on: April 3, 2026
13:21Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
Related Concept Videos
01:37Epigenetic Regulation
X-chromosome...
01:46Epigenetic Regulation
02:23Abnormal Proliferation